Kenya - English - Pharmacy and Poisons Board

svizera labs private limited turma india - rifampicin 150/ isoniazid 75 tablets - orodispersible tablet - rifampicin 150/ isoniazid 75 tablets - various

Kenya - English - Pharmacy and Poisons Board

svizera labs pvt ltd turbhe,navi mumbai - rifampicin 150/ pyrazinamide 400/ isoniazid 75/… - tablet - rifampicin 150/ pyrazinamide 400/ isoniazid 75/… - various

Kenya - English - Pharmacy and Poisons Board

macleods pharmaceuticals limited atlanta arcade church road near leela hotel - rifampicin 60 mg isoniazid 30 mg tablets… - dispersible tablet - rifampicin bp 60 mg isoniazid bp30 mg - antimycobacterials: combinations of drugs for

Kenya - English - Pharmacy and Poisons Board

macleods pharmaceuticals limited atlanta arcade church road andheri ( east) mumbai - rifampicin 60 mg isoniazid 60 mg dispersible… - dispersible tablet - rifampicin bp 60 mg isoniazid bp 60 mg - antimycobacterials: combinations of drugs for

Kenya - English - Pharmacy and Poisons Board

macleods pharmaceuticals limited atlanta arcade church road near leela hotel - rifampicin 60 mg isoniazid 30 mg pyrazinamide150… - dispersible tablet - rifampicin bp 60 mg isoniazid bp 30 mg … - antimycobacterials: combinations of drugs for

Kenya - English - Pharmacy and Poisons Board

macleods pharmaceuticals limited 304, atlanta arcade, marol church road, andheri - rifampicin isoniazid pyrazinamide - dispersible tablet - rifampicin bp 75 mg isoniazid bp 50 mg… - antimycobacterials: combinations of drugs for

Kenya - English - Pharmacy and Poisons Board

macleods pharmaceuticals limited 304, atlanta arcade, marol church road, andheri - rifampicin isoniazid - dispersible tablet - rifampicin bp 75 mg isoniazid bp 50 mg - antimycobacterials: combinations of drugs for

Ireland - English - HPRA (Health Products Regulatory Authority)

sandoz gmbh - rifampicin - capsule - 300mg milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 20 mg/ml - oral liquid - excipient ingredients: agar; sucrose; methyl hydroxybenzoate; propyl hydroxybenzoate; potassium sorbate; saccharin; polysorbate 80; diethanolamine; purified water; sodium metabisulfite; fragrance (perfume) - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 702 mg (equivalent: abacavir, qty 600 mg); lamivudine, quantity: 300 mg; dolutegravir, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; magnesium stearate; purified water; mannitol; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - trelavue is indicated for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-na?ve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents (dolutegravir, abacavir or lamivudine) in trelavue.